In this episode of StartUp Health NOW, we dive into one of the most fascinating innovation stories in health tech. Our guest is Chuck Papageorgiou, CEO of NeuroEM Therapeutics, a company that’s part of StartUp Health’s Alzheimer’s Moonshot Community and is making waves with a radically different approach to treating Alzheimer’s disease — using radio waves.
What started as a research study to prove that cell phones cause brain cancer led to an unexpected breakthrough: the very same radio frequencies used in phones appeared to improve brain health in mice with Alzheimer’s. The discovery sparked a scientific journey that has since included promising human trials, FDA Breakthrough Device designation, partnerships, and progress towards bringing this non-invasive, affordable, at-home therapy to millions.
Papageorgiou shares how NeuroEM’s wearable headset is helping untangle the brain’s toxic proteins, the science behind this counterintuitive tech, and why the impact could rival — or even surpass — that of current Alzheimer’s drugs.
If you're looking for an inspiring story about accidental genius ideas, bold leadership, and breakthrough innovation in brain health, this one’s a must-listen.



Are you ready to tell YOUR story? Members of our Health Moonshot Communities are leading startups with breakthrough technology-driven solutions for the world’s biggest health challenges. Exposure in StartUp Health Media to our global audience of investors and partners – including our podcast, newsletters, magazine, and YouTube channel – is a benefit of our Health Moonshot Community Membership. To schedule a call and see if you qualify to join and increase brand awareness through our multi-media storytelling efforts, submit our three-minute application. If you’re mission-driven, collaborative, and ready to contribute as much as you gain, you might be the perfect fit.
» Learn more and apply today.
Want more content like this? Sign up for StartUp Health Insider™ to get funding insights, news, and special updates delivered to your inbox.